These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28834862)

  • 1. Pharmaceutical Cost Savings in the Intensive Care Unit.
    Pennell BT; Murphy CV; Byrd C; Tubbs C
    Crit Care Nurs Q; 2017; 40(4):414-423. PubMed ID: 28834862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing the Rising Costs and High Drug Expenditures in Critical Care Pharmacy Practice.
    Flannery AH; Pandya K; Laine ME; Almeter PJ; Flynn JD
    Pharmacotherapy; 2017 Jan; 37(1):54-64. PubMed ID: 27995636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups.
    Claus BO; Robays H; Decruyenaere J; Annemans L
    J Eval Clin Pract; 2014 Dec; 20(6):1172-9. PubMed ID: 25470782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit.
    Dasta JF; Kane-Gill SL; Pencina M; Shehabi Y; Bokesch PM; Wisemandle W; Riker RR
    Crit Care Med; 2010 Feb; 38(2):497-503. PubMed ID: 19789442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2014 Dec; ():1-32. PubMed ID: 25771553
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceuticals and medical devices: cost savings.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulatory and Economic Considerations of Retinal Drugs.
    Shah AR; Williams GA
    Dev Ophthalmol; 2016; 55():376-80. PubMed ID: 26502165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality improvement and cost savings after implementation of the Leapfrog intensive care unit physician staffing standard at a community teaching hospital.
    Parikh A; Huang SA; Murthy P; Dombrovskiy V; Nolledo M; Lefton R; Scardella AT
    Crit Care Med; 2012 Oct; 40(10):2754-9. PubMed ID: 22824939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of drug importation on community pharmacy and patient care.
    Shepherd MD
    J Am Pharm Assoc (2003); 2007; 47(3):319-20, 323-4, 327. PubMed ID: 17510027
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic stress and misaligned incentives in critical care medicine in the United States.
    Dorman T; Pauldine R
    Crit Care Med; 2007 Feb; 35(2 Suppl):S36-43. PubMed ID: 17242605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit.
    Chuang LC; Sutton JD; Henderson GT
    Hosp Pharm; 1994 Mar; 29(3):215-8, 221. PubMed ID: 10132696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 14. Possibilities for cost containment in intensive care.
    Thungjaroenkul P; Kunaviktikul W
    Nurs Health Sci; 2006 Dec; 8(4):237-40. PubMed ID: 17081150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICU early physical rehabilitation programs: financial modeling of cost savings.
    Lord RK; Mayhew CR; Korupolu R; Mantheiy EC; Friedman MA; Palmer JB; Needham DM
    Crit Care Med; 2013 Mar; 41(3):717-24. PubMed ID: 23318489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of a progressive care environment for neurosurgical patients.
    Schneider MA; Pomidor MA
    J Neurosci Nurs; 2014 Oct; 46(5):306-11. PubMed ID: 25188685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth of intensive care unit resource use and its estimated cost in Medicare.
    Milbrandt EB; Kersten A; Rahim MT; Dremsizov TT; Clermont G; Cooper LM; Angus DC; Linde-Zwirble WT
    Crit Care Med; 2008 Sep; 36(9):2504-10. PubMed ID: 18679127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-benefit analysis of the implementation of automated drug-dispensing systems in Critical Care and Emergency Units].
    Poveda Andrés JL; García Gómez C; Hernández Sansalvador M; Valladolid Walsh A
    Farm Hosp; 2003; 27(1):4-11. PubMed ID: 12607010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin use guidelines and outcome in a surgical intensive care unit.
    Charles A; Purtill M; Dickinson S; Kraft M; Pleva M; Meldrum C; Napolitano L
    Arch Surg; 2008 Oct; 143(10):935-9; discussion 939. PubMed ID: 18936370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restricted Albumin Utilization Is Safe and Cost Effective in a Cardiac Surgery Intensive Care Unit.
    Rabin J; Meyenburg T; Lowery AV; Rouse M; Gammie JS; Herr D
    Ann Thorac Surg; 2017 Jul; 104(1):42-48. PubMed ID: 28027733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.